



BIODIEM LTD

ABN 20 096 845 993

Level 4,

100 Albert Rd,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.biodiem.com

Announcement

Influenza Vaccine Clinical Trial commences in China

Melbourne, 31 March 2016:

BioDiem is pleased to announce the commencement of clinical trials in China for the LAIV influenza vaccine.

Changchun BCHT Biotechnology Co (BCHT) has made rapid progress in the development of its 'flu vaccine in China since licensing the LAIV technology from BioDiem just three years ago. During this time, BCHT has developed the manufacturing process for the vaccine, received IND approval from the Chinese FDA and has now started the clinical trials required for approval to market the vaccine in China.

Dr Jinchang Wu, Director, R&D and International Affairs for BCHT, said "We have now reached another important milestone in the commercialisation of the LAIV intranasal 'flu vaccine in China. Our clinical trial is a Phase I safety study. It will enrol children from 3 years of age and adults over the next three months".

BioDiem's CEO, Julie Phillips said, "This is an important development for our company. BCHT, our licensee in China, has moved quickly down the commercialisation path for their influenza vaccine. An intranasal 'flu vaccine presents many advantages, especially for children and for those who dislike needles. We are excited about the commercial potential for the LAIV vaccine in China. Royalties will flow to BioDiem from sales of the product into the private market in China."

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on product sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has

spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit www.opalbiosciences.com.

Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email jphillips@biodiem.com

Twitter @biodiem